CURRICULUM VITAE
Banu Arun, MD
PRESENT TITLE AND AFFILIATION
Primary Appointment
Associate Professor (Tenure Track), Department of Breast Medical Oncology, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Co-Medical Director for Clinical Cancer Genetics, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor (Tenure Track), Department of Clinical Cancer Prevention, Division of OVP,
Cancer Prevention and Population Sciences, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
OFFICE ADDRESS
The University of Texas M. D. Anderson Cancer Center
Department of Breast Medical Oncology - Unit 1354
1515 Holcombe Blvd
Houston, TX 77030
Room Number: CPB5.3450
Phone: (713) 792-2817
Fax: (713) 794-4385
Email: barun@mdanderson.org
EDUCATION
Degree-Granting Education
University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey, MD, 1990
Postgraduate Training
Internship, Internal Medicine, University of Istanbul, Cerrahpasa Medical School University
Hospital, Istanbul, Turkey, Ugur Ulku, 1990−1991
Residency, Internal Medicine, University of Istanbul, Cerrahpasa Medical School, Istanbul,
Turkey, Ugur Ulku, 1991−1994
Fellowship, Hematology and Oncology, Vincent T. Lombardi Cancer Center Georgetown
University, Washington, DC, Edward Gelmann, Kevin Cullen, 1994−1997
CREDENTIALS
Licensures
Active
TX, K5781, 1/1997
AL, 21263, 1/1997
EXPERIENCE/SERVICE
Academic Appointments
Assistant Professor, Division of Oncology and Hematology, Harold C. Simmons Cancer Center,
The University of Texas Southwestern Medical Center, Dallas, TX, 7/1997−7/2000
Banu Arun, MD
Assistant Professor (NTCA), Department of Breast Medical Oncology, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 8/2000−8/2004
Assistant Professor (NTCA), Department of Clinical Cancer Prevention, The University of Texas
M. D. Anderson Cancer Center, Houston, TX, 3/2002−8/2004
Associate Professor (Tenure Track), Department of Clinical Cancer Prevention, Division of OVP,
Cancer Prevention and Population Sciences, The University of Texas
M. D. Anderson Cancer Center, Houston, TX, 9/2004−present
Associate Professor (Tenure Track), Department of Breast Medical Oncology, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2004−present
Administrative Appointments/Responsibilities
Director of Medical Oncology for Breast Cancer, Parkland Memorial Hospital, The University of
Texas Southwestern Medical Center, Dallas, TX, 1/1999−1/2000
Co-Medical Director for Clinical Cancer Genetics, The University of Texas
M. D. Anderson Cancer Center, Houston, TX, 9/2003−present
Other Appointments/Responsibilities
Faculty Medical Oncologist, Zale Lipshy University Hospital, UT Southwestern Medical Center,
Dallas, TX, 7/1997−7/2000
Faculty Member, Graduate School of Biomedical Sciences, Houston, TX, 9/2006−present
Institutional Committee Activities
Breast Cancer Serum/DNA Oversight Committee, Member, 8/2003−present
Clinical Cancer Genetics Steering Committee, Member, 8/2003−present
Breast Medical Oncology Education Committee, Member, 6/2004−present
Tumor Bank Committee, Member, 8/2005−present
Breast Cancer Serum/DNA Oversight Committee, Chair-Elect, 9/2006−8/2007
Credentials Committee of the Medical Staff, Member, 9/2006−present
US-Middle Eastern Partnership for Breast Cancer, Committee Chair, 2007−present
Breast Cancer Serum/DNA Oversight Committee, Chair, 8/2007−present
Organizing Committee Global Academic Programs Conference, Member, 12/2007−present
HONORS AND AWARDS
American Association for Cancer Research Scholarship, 1996
RESEARCH
Grants and Contracts
Funded
Principal Investigator, Characterization of Estrogen Receptor Negative Breast Cancer
Related Markers by Immunohistochemistry which are identified using Microarray Gene
Analysis in Breast Cancer Specimens, U10 CA045809 19, NIH/NCI, 8/2002−5/2012,
$465,270
Principal Investigator, Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec)
for Postmenopausal Patients with ER and/or Positive Metastatic Breast Cancer, CS200300008794AB, Novartis, 6/2003−12/2009, $86,426
Co-Leader, Treatment of metastatic breast cancer with gene modified mesenchymal stem
cells Period of grant, P50 CA116199-04, NIH/NCI, 2005−2010, $799,777
Principal Investigator, Lynne Cohen High Risk Screening & Prevention Project for Ovarian &
Breast Cancer, Lynne Cohen Foundation, 4/2005−3/2011, $120,000
Page 2 of 26
Banu Arun, MD
Principal Investigator, Pilot study evaluating the significance of the HER2/neu 1655V
polymorphism in Hispanic women with breast cancer and women who are at increased risk to
develop breast cancer, U54-CA96300, NIH/NCI, 5/2005−present, $50,000
Collaborator, Biobehavioral Effects of Yoga During Cancer Treatment, 5-R21 CA 102385-02,
NIH/NCI, PI - Cohen, 7/2005−6/2009, $146,963
Principal Investigator, Gemcitabine and R115777 Combination of Therapy for Metastatic
Breast Cancer, N01 CM-17003, NIH/NCI, 11/2005−11/2008, $313,168
Co-Investigator, Early Therapeutic Development with Phase II Emphasis, N0 CM-62202,
NIH/NCI, PI - Dr. Stewart, 1/2006−12/2008, $30,102
Collaborator, Effects of Tibetan Yoga on Fatigue and Sleep in Cancer, 1 R01-CA105023-01,
NIH/NCI, PI - Cohen, 3/2006−2/2011, $324,660
Principal Investigator, A Phase I Prevention Study of Atorvastatin in Women at Increased
Risk for Breast Cancer, N01 CN-35159, NIH/NCI, 9/2006−8/2009, $521,333
Collaborator, Discovery and Clinical Validation of Cancer Biomarkers Using Printed Glycan
Array, U01 CA128526-01, NIH/NCI, PI - Hufjlet, 8/2007−8/2012, $1,439,147
Collaborator, 1%, DNA damage as a Biomarker of Risk of Breast Cancer, Susan G. Komen
Breast Cancer Foundation, 2/1/2009−1/31/2011, $237,573
Co-Principal Investigator, Development of novel early detection and prevention strategies for
ER negative breast cancer, KG091020, Susan G. Komen Breast Cancer Foundation,
$615,980 ($123,196/year)
Pending
Co-Investigator, 5%, Estrogen receptor beta: Potential role in prevention, progression and
therapeutic resistance to endocrine therapies of breast cancer, Cancer Prevention Research
Institution of Texas, 3/1/2010−2/28/2014, $53,551 ($12,800/year)
Co-Principal Investigator, 20%, Germline mutation of novel breast cancer susceptibility
genes, RP100123, Cancer Prevention Institute of Texas, PI - Dai, 3/1/2010−2/28/2014
($421,793/year)
Principal Investigator, 1%, Evaluation of hereditary cancer risk in family members of patients
with or without BRCA mutations, Susan G. Komen Breast Cancer Foundation,
4/1/2010−3/31/2011, $718,068
Principal Investigator, 1%, Targeting P70S6K in metastatic breast cancer, Susan G. Komen
Breast Cancer Foundation, 5/1/2010−4/30/2013, $180,000 ($60,000/year)
Co-Investigator, 1%, Evaluation and validation of enhanced BRCAPRO and its adaption for
primary settings, Cancer Prevention Research Institute of Texas, PI - Biswas,
7/1/2010−6/30/2012, $39,877 ($19,644/year)
Collaborator, 5%, Examining the neural substrates fo acupuncture for chemotherapy-induced
nausea, NIH/NCI, 7/1/2010−6/30/2012 ($236,508/year)
Co-Principal Investigator, 10%, Germline mutation of NHERF2 and its network genes in
hereditary breast cancer, NIH/NCI, PI - Dai, 7/1/2010−3/30/2015 ($269,425/year)
Co-Investigator, Development of novel strategies of early detection and prevention for
HER2+, ER- breast cancer, Susan G. Komen Breast Cancer Foundation, PI - Yu, $1,500,000
Completed
Principal Institutional Investigator, Breast Project, Chemoprevention in genetically-identified
high-risk groups: Interactive Research & Development Project, CA 98012, NIH/NCI,
3/1999−8/2006, $1,043,704
Page 3 of 26
Banu Arun, MD
Principal Investigator-MDACC, Targretin for modifying immunophenotyipic markers related to
breast cancer progression in breast tissue from genetically identified high risk women, U19
CA086809, Baylor College of Medicine, 9/1999−8/2006, $170,644
Principal Investigator, An exploratory study to identify potential surrogate endpoint
biomarkers that are modulated by tamoxifen vs placebo in women with an increased risk for
breast cancer, RFP N01-CN-95139, NIH/NCI, 10/1999−10/2003, $366,666
Collaborator, Characterization of Estrogen Receptor Negative Breast Cancer Related
Markers by Immunohistochemistry which are Identified Using Microarray Gene Analysis in
Breast Cancer Specimens, U10 CA 045809-14, NIH/NCI, 9/2002−5/2007, $294,603
Principal Investigator, Phase 2, Randomized, open label study of single agent CI-1033 in
patients with metastatic breast cancer, CS2002-00007174SP, Pfizer, 9/2002−9/2007,
$139,000
Principal Investigator, Pilot study of biomarker modulation with a COX-2 inhibitor using ductal
lavage in women at high risk for Breast Cancer, R03 CA 97557-01, NIH/NCI, 9/2002−8/2008,
$151,000
Principal Investigator, Evaluation of antiproliferative effects of Arimidex in ductal lavage fluid
in women with breast cancer, LAB02-400, Astra-Zeneca, 10/2002−10/2007, $41,550
Principal Investigator, Study of biomarker modulation with a COX-2 inhibitor using ductal
lavage in women at high risk of Breast Cancer, CS2002-00007771RM, Pharmacia,
12/2002−2/2007, $77,190
Collaborator, The proposed study will involved three collaborative research programs: 1)
Evaluating herbal/nature product, 1 R21 CA108084-01, NIH/NCI, PI - Cohen, 9/2003−8/2005,
$263,250
Principal Investigator, Prevelance of BRCA1 and BRCA2 mutations in women with ductal
carcinoma., Texas Federation of Business & Professional Women, 6/2005−6/2007, $7,000
Principal Investigator, Genetic Modifiers of BRCA1 and BRCA2, Duke University,
7/2006−7/2008, $37,500
Not Funded
N/A
Protocols
Funded
Principal Investigator, Pilot study evaluating the significance of the HER2/neu 1655V
polymorphism in Hispanic women with breast cancer and women who are at increased risk to
develop breast cancer, LAB05-0158, 2000
Principal Investigator, Follow-up of women who are at increased risk for developing breast
cancer, LAB03-0479, 2001
Principal Investigator, Phase 1 clinical and pharmacokinetic evaluation of oral CI-1033 in
combination with docetaxel in the treatment of patients with advanced nonhematologic
malignancies, DM02-304, 2002−2003, $72,500, Pfizer
Principal Investigator, Phase II randomized open-label study of single Agent CI-1033 in
patients with metastatic breast cancer, DM02-163, 2002−2003
Principal Investigator, Evaluation of antiproliferative effects of anastrazole in ductal lavage in
patients with breast cancer, LAB02-400, 2002−present, $41,550, Astra-Zeneca
Principal Investigator, Pilot study of biomarker modulation with a COX-2 inhibitor using ductal
lavage in women at high risk for breast cancer with evaluation of proteomics, ID02-458,
2002−present, $50,000, NIH
Page 4 of 26
Banu Arun, MD
Principal Investigator, Phase II study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec)
for postmenopausal patients with ER and/or positive metastatic breast cancer, DM02-0384,
2003−2008, $211,688, Novartis
Principal Investigator, Pilot biomarker modulation study using a PPAR-gamma agonist
Rosiglitazone in women who are at increased risk to develop breast cancer (Use of
Rosiglitazone in breast cancer), LAB04-0306, 2005−2006
Principal Investigator, Gemcitabine and R115777 combination therapy for metastatic breast
cancer, 2003-0992, 2005−2008, $313,168, NCI
Principal Investigator, Phase II, open-label, non-comparative, international, multicentre study
to assess the efficacy and safety of KU-0059436 given orally twice daily in patients with
advanced BRCA1- or BRCA2-associated breast cancer., 2007-0431, 2007−present,
$230,711, Astra-Zeneca (KuDOS)
Grant Reviewer/Service on Study Sections
Susan G. Komen Breast Cancer Research Program, Risk and Prevention Review Committee,
Foundation, Member, 2000
Canadian Breast Cancer, Foundation, Member, 2001
Susan G. Komen Breast Cancer Research Program, Treatment Systemic Review Committee,
Foundation, Member, 2001
Cancer Research United Kingdom, Other, Member, 2002
Susan G. Komen Breast Cancer Research Program, Risk and Prevention Review Committee,
Foundation, Member, 2003
Susan G. Komen Study Section Leader for Risk, Prevention and Epidemiology, Foundation,
Section Leader, 2003
American Society of Clinical Oncology, ASCO, Member, Education Committee, 2005
National Comprehensive Cancer Network, (NCCN), Member, Breast Cancer Risk Reduction
Panel, 2005
American Association for Cancer Research, AACR, Member, Frontiers in Cancer Prevention
Scientific Review Committee, 2007
PUBLICATIONS
Peer-Reviewed Original Research Articles
1. Arun B, Berberian B, Azumi N, Frankel SR, Luksenburg H, Freter C. Sweet's syndrome
during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia.
Leuk Lymphoma 31(5-6):613-5, 1998.
2. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ. The
mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast
tumor suppressor gene. Breast Cancer Res Treat 47(3):269-81, 1998.
3. Kilic G, Cardillo M, Ozdemirli M, Arun B. Human papillomavirus 18 oncoproteins E6 and E7
enhance irradiation- and chemotherapeutic agent-induced apoptosis in p53 and Rb mutated
cervical cancer cell lines. Eur J Gynaecol Oncol 20(3):167-71, 1999.
4. Meehan KR, Arun B, Gehan EA, Berberian B, Sulica V, Areman EM, Mazumder A, Lippman
ME. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic
stem cell transplantation for breast cancer. Bone Marrow Transplant 23(7):667-73, 1999.
5. Ozguroglu M, Arun B, Erzin Y, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti
S, Berkarda B. Serum cardiolipin antibodies in cancer patients with thromboembolic events.
Hemost 5(3):181-184, 1999.
Page 5 of 26
Banu Arun, MD
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Arun B, Slack R, Gehan E, Spitzer T, Meehan KR. Survival after autologous hematopoietic
stem cell transplantation for patients with inflammatory breast carcinoma. Cancer 85(1):93-9,
1999.
Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp WC, Janik
JE. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with
hairy cell leukemia. Cancer J Sci Am 6(1):21-4, 2000.
Ozguroglu M, Arun B, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti S,
Berkarda B. Serum erythropoietin level in anemic cancer patients. Med Oncol 17(1):29-34,
2000.
Arun B, Kilic G, Ashfaq R, Saboorian HM, Gokaslan T. Endothelin converting enzyme-1
expression in endometrial adenocarcinomas. Cancer Invest 19(8):779-82, 2001.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B,
Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly
docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
J Clin Oncol 20(7):1800-8, 2002.
Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R. Correlation of Bcl-2 and
p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer
98(12):2554-9, 2003.
Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA,
Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi
GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast
cancer reliably identify routine prognostic markers and reveal large-scale molecular
differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res
9(7):2406-15, 2003.
Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A,
Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I
and II study of exisulind in combination with capecitabine in patients with metastatic breast
cancer. J Clin Oncol 21(18):3454-61, 2003.
Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, 3rd, Pusztai
L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with
gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249-54, 2003.
Altundag K, Arun B. Amerikan Klinik Kanser Cemiyeti (ASCO) Toplantisindan Izlenimler:
Meme Kanserinin Adjuvan Tedavisinde Bisfosfonatlarin Rolu. The Turkish Journal of
Hematology and Oncology 14(3):179-181, 2004.
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA,
Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS,
Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel
chemotherapy. Cytokine 25(3):94-102, 2004.
Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV,
Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral
prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86,
2004.
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J,
Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi
GN, Pusztai L. Gene expression profiles predict complete pathologic response to
neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in
breast cancer. J Clin Oncol 22(12):2284-93, 2004.
Altundag K, Altundag O, Gunduz M, Arun B. Possible interaction between activator protein-1
and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen.
Med Hypotheses 63(5):823-6, 2004.
Ozguroglu M, Avci B, Turna H, Esen G, Arun B, Celik V, Serdengecti S. Should
mammographic screening be done in primary ovarian cancer? A case control study in Turkish
women. Med Oncol 21(2):139-43, 2004.
Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V,
Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess
KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers
Page 6 of 26
Banu Arun, MD
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
associated with immature cell type and short duration of prior breastfeeding. Endocr Relat
Cancer 12(4):1059-69, 2005.
Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. CCR7 and
CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Clin Cancer Res 11(16):5686-93, 2005.
Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N,
Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C,
Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton
MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA,
Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. Characterization of a recurrent
germ line mutation of the E-cadherin gene: implications for genetic testing and clinical
management. Clin Cancer Res 11(15):5401-9, 2005.
Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq R. Expression
of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol 26(3):271-4,
2005.
Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R. Loss of FHIT expression
in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers
Prev 14(7):1681-5, 2005.
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P,
Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L.
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc
Natl Acad Sci U S A 102(23):8315-20, 2005.
Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN,
Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid
protein expression between healthy women and those with breast cancer demonstrated by
time-of-flight mass spectrometry. Breast Cancer Res Treat 89(2):149-57, 2005.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green
MC, Arun B, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin
AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic
complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and
epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor
receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 2005.
Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in
extracellular matrix inhibit tumor invasion. Mol Cancer 4:33, 2005.
Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R,
Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary
breast carcinoma: disease features at presentation. Cancer 103(12):2466-72, 2005.
Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van
Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the
wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety,
efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107(5):935-44, 2006.
Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun B, Lovalvo JL, Eiseman IA, Olson
SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic study of oral CI-1033 in
combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12(14 Pt
1):4274-82, 2006.
Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB,
Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in
extended families. J Clin Oncol 24(3):354-60, 2006.
Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F,
Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction
interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Cancer 107(12):2745-51, 2006.
Sneige N, Liu B, Yin G, Gong Y, Arun B. Correlation of cytologic findings and chromosomal
instability detected by fluorescence in situ hybridization in breast fine-needle aspiration
specimens from women at high risk for breast cancer. Mod Pathol 19(5):622-29, 2006.
Page 7 of 26
Banu Arun, MD
36. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L,
Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact
of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma
recurrence and contralateral breast carcinoma development in patients with ductal carcinoma
in situ treated with breast-conserving therapy. Cancer 106(1):42-50, 2006.
37. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi
GN, Buchholz T. Phase I study of capecitabine in combination with temozolomide in the
treatment of patients with brain metastases from breast carcinoma. Cancer 107(6):1348-54,
2006.
38. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan
VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim
J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL,
Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee
JJ, Dubinett SM, Engstrom PF, Meyskens FL, Jr, O'Shaughnessy J, Hawk ET, Levin B,
Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of
molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move
forward. Clin Cancer Res 12(12):3661-97, 2006.
39. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun B,
Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH.
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with
BRCA mutations. Obstet Gynecol 108(3 Pt 1):515-20, 2006.
40. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera
GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during
prophylactic mastectomy. Cancer 107(7):1440-7, 2006.
41. Vogel K, Atchley DP, Erlichman J, Broglio K, Ready KR, Valero V, Amos CI, Hortobagyi GN,
Lu KH, and Arun B. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation
prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol
25(29):4635-41, 2007.
42. Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F,
Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA
Annu Symp Proc:995, 2007.
43. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H,
Gong Y, Browne D, Hortobagyi G, Sneige N. Comparison of ductal lavage and random
periareolar fine needle aspiration as tissue acquisition methods in early breast cancer
prevention trials. Clin Cancer Res 13(16):4943-48, 2007.
44. Yang WT, Dryden M, Broglio, K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi
G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast
cancers in young premenopausal women. Breast Cancer Res Treat 111(3):405-10, 2007.
45. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortonagyi GN, Arun B.
Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007.
46. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ,
Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib
mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical
activity and biological correlations. Ann Oncol 19(10):1713-9. e-Pub 5/2008.
47. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM,
Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun
BK, Hortobagyi GN. Ductal Carcinoma In Situ: State of the Science and Roadmap to
Advance the Field. J Clin Oncol 27(2):279-88. e-Pub 12/2008.
48. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin
CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol
Morphol 16(6):530-4, 12/2008.
49. Atchley D, Albarracin C, Lopez A, Valero V, Amos V, Gonzalez-Angulo A, Hortobagyi G,
Arun B. Clinical and pathological characteristics of patients with BRCA-Positive and BRCANegative breast cancer. JCO 26(26):4282-8, 2008.
Page 8 of 26
Banu Arun, MD
50. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of
breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer
J 14(1):62-8, 2008.
51. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun
B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy
in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol
135(1):141-8, 2008. e-Pub 2008.
52. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy Wang B, Hortobagyi GN, Buzdar AU,
Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer
compared to healthy volunteers. Br J Cancer 99(1):68-71, 2008.
53. Batista L, Lu KH, Beahm EK, Arun B, Bodukra D, Meric-Bernstam F. Coordinated
prophylactic surgical management for women with hereditary breast-ovarian cancer
syndrome. BMC Cancer 8:101, 2008.
54. Wang H, Arun B, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and
IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.
Breast J 14(3):261-7, 2008.
55. Rivera E, Mejia J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Hortobagyi G,
Valero V. Phase III study comparing the use of docetaxel on an every-3-week versus weekly
schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455-61, 2008.
56. Brewster A, Hortobagyi G, Broglio K, Kau S, Santa-Maria C, Arun B, Amad U. Buzdar A,
Booser D, Valero V, Esteva F. Residual Risk of Breast Cancer Recurrence 5 years after
Adjuvant Therapy. J Natl Cancer Inst 100(16):1179-83, 2008.
57. Akar U, Chaves-Reyes A, Barria M, Tari A, Saungino A, Kondo Y, Kondo S, Arun B, LopezBerestein G, Ozpolat B. Silencing of Bcl-2 expression by small Interfering RNA induces
autophagic cell death in MCF-7 breast cancer cells. Autophagy 4(5):669-79, 2008.
58. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam
F, Kuerer H, Hortobagyi GN, Albarracin CT. High Prevalence of Pre-invasive Lesions
Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prev Res (Phila Pa). e-Pub
1/2009.
59. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM,
Hartmann LC, Holland R, Winchester DJ, Winchester DJ, Anderson BO, Arun BK, Bartelink
H, Bernard P, Bonanni B, Cady B, Clough KB, Feig SA, Heywang-Köbrunner SH, Howell A,
Isaacs C, Kopans DB, Mansel RE, Masood S, Palazzo JP, Pressman PI, Solin LJ, Untch M.
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk
management, April, 2007. Breast J 15(1):4-16, Jan-Feb, 1/2009.
60. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN,
Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer.
Cancer 115(4):725-730, 2/2009.
61. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Caro M, Wei C, MericBernstam F, Brown P, Arun BK, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta
signaling and increased COX2 expression in high risk women with increased mammographic
breast density. Breast Cancer Research and Treatment. e-Pub 2/2009.
62. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF,
Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with
unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer
115(5):962-971, 3/2009.
63. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo
AM, Bodurka DC, Lu KH, HortobagyiGN, Arun BK. Perception of screening and risk
reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):15981604, 4/2009.
64. Visvanathan K, Chlebowski, TR, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz
C, Pritchard KI, Hagerty K, Arun BK, Garber J, Vogel VG, Wade JL Brown P, Cuzick J,
Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline
update on the use of pharmacologic interventions including tamoxifen, raloxifene, and
aromatase inhibition for breast cancer risk reduction. Journal of Clinical Oncology
27(19):3235-3258. e-Pub 5/2009.
Page 9 of 26
Banu Arun, MD
65. Rixe O, Franco S, Yardley D, Johnston S, Martin M, Arun BK, Letrent S. A randomized,
phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor canertinib (CI1033) in patients with pretreated metastatic breast cancer. Cancer Chemotherapy and
Pharmacology. In Press.
66. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, Tuzikov A, Galanina O,
Arun BK, Lu K, Bovin N. Anti-carbohydrate antibodies of normal sera: Findings, surprises,
and challenges. Moleculer Immunology. In Press.
67. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam F, Lu K,
Hortobagyi G, Arun BK. Breast and ovarian cancer risk management decisions of women
with BRCA1/2 variants of uncertain significance. The Breast Journal. In Press.
68. Arun BK, Granville LA, Guosheng Y, Middleton LP, Dawood S, Kau S, Kamal A, Hsu L,
Hortobagyi GN, Sahin AA. Gluthatione-S-transferase-pi (GST-pi) Expression in Early Breast
Cancer: Association with Outcome and Response to Chemotherapy Cancer Investigation.
Cancer Investigation. In Press.
69. Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Wei NQ, Cohen L. Yoga
Improves Quality of Life and Benefit Finding in Women Undergoing Radiotherapy for Breast
Cancer. Journal of the Society for Integrative Oncology. In Press.
Invited Articles
1. Longo DL, Arun B. Clinical approach to cervical lymphadenopathy. Consultant 36(11):23452352, 1996.
2. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis 29(23):100-10, 1999.
3. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation. clinical and
pathophysiological mechanisms and manifestations. Haemostasis 29(2-3):111-34, 1999.
4. Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan: pharmacologic and clinical
issues. Expert Opin Pharmacother 2(3):491-505, 2001.
5. Arun B, Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr Relat Cancer
9(1):15-32, 3/2002.
6. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother
3(6):681-91, 6/2002.
7. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for
breast cancer metastasis and survival. Semin Radiat Oncol 12(4):319-28, 2002.
8. Arun B. Preventive Strategies for Breast Cancer. Breast Cancer: Management and
Treatment Updates 1:1-11, 2002.
9. Arun B. An overview of breast cancer prevention trials. The American Journal of Oncology
Review:492-94, 2003.
10. Arun B. Management of women at high risk for breast cancer. JNCCN 1(1):S71-77, 2003.
11. Arun B. Ductal lavage and risk assessment of breast cancer. Oncologist 9(6):599-05,
11/2004.
12. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention.
Semin Oncol 31(2 Suppl 7):22-9, 2004.
13. Altundag K, Esteva FJ, Arun B. Monoclonal antibody-based targeted therapy in breast
cancer. Curr Med Chem Anticancer Agents 5(2):99-106, 2005.
14. Arun B, Brown PH, Garber JE. Risk assessment and efficacy of pharmacologic agents in
breast cancer. Updates in Current Clinical Practices 1:5-8, 2006.
15. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE,
Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L,
Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E,
Ward JH. Breast cancer risk reduction. J Natl Compr Canc Netw 5(8):676-01, 2007.
Editorials
N/A
Other Articles
Page 10 of 26
Banu Arun, MD
1.
Arun B. Commentary on the article Fenretinide Breast Cancer Prevention Trial: Drug and
Retinol Plasma Levels in Relation to Age and Disease Outcome. Breast Disease: A Year
Book Quarterly, 2003.
Abstracts
1. Arun B, Cardillo M, Ozdemirli M, Kilic G. Human papilloma virus 18 E6 and E7 enhances
irradiation-and chemotherapeutic agent induced apoptosis in P53 and RB mutated cervical
cancer cell line. Proc Am Soc Oncol 17:562a (#2158), 1998.
2. Ashfaq R, Yardley DA, Frankel EP, Arun B. Bcl-2 and p53 expression in breast cancer and
their metastatic lymph nodes. Proc Am Soc Oncol 19:667a (#2631), 2000.
3. Pusztai L, Mendoza TR, Reuben JM, Broemeling L, Lara J, Rivera E, Arun B, Esteva F,
Valero V, Hortobagyi GN, Cleeland CS. Correlation between fatigue and musculoskeletal
symptoms and chemotherapy-induced release of inflammatory cytokines in the blood. Proc.
25th San Antonio Breast Cancer Symposium, San Antonio, TX 7 (#551), 2001.
4. Pusztai L, Symmans WF, Ayers M, Stec J, Clark E, Hess K, Sniege N, Esteva FJ, Arun B,
Booser D, Rosales M, Hortobagyi GN. Correlation between gene expression profiles obtained
from single passage fine needle aspirations (FNA) of breast cancer and clinicopathologic
parameters. Clinical Cancer Research 7(11 Suppl. S):196, 2001.
5. Arun B, Yen C, Foster B, Gaynor R, Ashfaq R. Cyclooxygenase-2 expression in breast
cancer and metastatic lymph node. Proc Am Soc Oncol 20:8b (#1781), 2001.
6. Arun B, Yardley DA, Pusztai L, Gaynor R, Ashfaq R. Expression of bcl-2 and p53 in breast
cancer and their metastatic lymph nodes. Proc Am Ass Cancer Res 42:220 (#1178), 2001.
7. Arun B, Zhang H, Mirza NQ, Hortobagyi GN, Hung M, Meric F. Growth inhibition of breast
cancer cells by celecoxib. Breast Cancer Research and Treatment 69(3):171a, 2001.
8. Ashfaq R, Foster B, Kilic G, Cichon Y, Gaynor R, Arun B. Loss of FHIT expression in primary
breast cancer correlates with p53 expression and inversely with Bcl-2 expression. Proc Am
Soc Oncol 20:331b (#3075), 2001.
9. Rivera E , Arun B, Royce M, Adinin R, Valero V, Hoelzer K, Walters R, Wade III J, Pusztai L,
Hortobagyi GN. Phase II study of Gemcitabine (G) and Doxil (D) combination chemotherapy
in patients with metastatic breast cancer: preliminary results. Proc. 25th San Antonio Breast
Cancer Symposium, San Antonio, TX (#551), 2001.
10. Puzstai L, Neally K, Pallansch P, Rivera E, Arun B, Valero V, Cristofanilli M, Hortobagyi GN.
Phase I-II study to evaluate safety and efficacy of Capecitabine (XELODA) and Exisulind
(APOPTOSYN) combination therapy in patients with metastatic breast cancer. Breast Cancer
Research and Treatment 69(3):433a, 2001.
11. Sikov WM, Akerley W, Kahanic S, Mangalik A, Arun B, Houston GA, Perry MC, Bertoli L,
Kugler J. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus
standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC). Proc Am Soc
Oncol 21:34a (#134), 2002.
12. Arun B, Multani A, Rivera E, Valero V, Pusztai L, Rosales M, Cristofanilli M, Booser DJ,
Hortobagyi GN, Pathak S. Telomeric DNA content is increased in blood of patients with
breast cancer. Proc Am Soc Oncol 21:439a (#1753), 2002.
13. Cristofanilli M, Khrisnamurthy S, Guerra L, Bisotooni K, Arun B, Walters R, Booser D, Coffee
K, Valero V, Hortobagyi GN. Ad5CMV-p53 combined with Docetaxel (T) and Doxorubicin (D)
as induction chemotherapy (IC) for patients with locally advanced breast cancer (LABC):
preliminary report of safety and efficacy. Proc Am Soc Oncol 22:241b (#967), 2003.
14. Goncharuk V, Arun B, Middleton L, Sahin, A. Assessment of actin-binding fascin expression
in stage I and II invasive breast cancer. A significant correlation with aggressive clinical
behavior. Modern Pathology 16(1):39A, 2003.
15. Arun B, Kamal A, Middleton L, Wang X, Kau SW, Smith TL, Esteva F, Hortobagyi GN. BclExpression predicts regional lymph node metastasis in early breast cancer. Proc Am Soc
Oncol 22:862a (#3464), 2003.
16. Moshin SK, Elledge RM, Arun B, Miller A, Wu K, Johnson K, Lamph WW, Browh PH. Breast
cancer prevention using RXR-selective retinoid (Targretin) in high risk women initial report of
a phase II randomized clinical trial. 26th Annual Breast Cancer Symposium, San Antonio, TX
82(1):S176 (#1027), 2003.
Page 11 of 26
Banu Arun, MD
17. Albarracin C, Arun B, Sahin A. Cell-Specific dysregulation of annex in I expression in breast
cancer. Modern Pathology 16(1):21A, 2003.
18. Cristofanilli M, Reuben JM, Fritsche HA, Kau S-W, Lara J, Arun B, Valero V, Chedid S, Doyle
GV, Miller MC, Allard J, Terstappen LWMM, Hortobagyi GN. Circulating tumor cells: A novel
prognostic factor for newly diagnosed metastatic breast cancer. Proc Am Ass Can Res 44
(#LB126), 2003.
19. Lu K, Beahm E, Arun B, Boudurka-Bevers D, Sun C, Miller M, Hunt K, Ames F, Strong L,
Meric-Bernstam F. Coordinated prophylactic surgical management for women with breastovarian cancer syndrome. Proc AACR Frontiers in Cancer Prevention Research 2nd Annual
International Conference, Phoenix, AZ (#C190), 2003.
20. Arun B, Lammey J, Valero V, Babiera G, Cristofanilli M, Smith TL, Hortobagyi GN, Sneige N.
Ductal lavage for short-term breast cancer chemoprevention trials. Proc AACR Frontiers in
Cancer Prevention Research 2nd Annual International Conference, Phoenix, AZ (#A129),
2003.
21. Arun B, Kamal A, Middleton L, Wang X, Smith TL, Esteva F, Hortobagyi G, Sahin A.
Evaluation of biomarkers to predict regional lymph node metastasis in early breast cancer; a
significant correlation with BCL-2 expression. Proc Am Ass Can Res 44:545 (#2400), 2003.
22. Lee P, Liu JS, Arun B, Sahin A. Expression of androgen receptor coactivator 70 in stage I
and II invasive breast cancer. 16(1):38A, 2003.
23. Gokhale S, Albarracin C, Arun B, Middleton L, Sahin A. Immunohistochemical expression of
prostate specific antigen in normal breast tissue and breast neoplasms. Modern Pathology
16(1):29A, 2003.
24. Arun B, Bariera G, Lammey J, Hortobagyi G, Sneige N. Phase II chemoprevention trial of
Celecoxib using ductal lavage. 26th Annual San Antonio Breast Cancer Symposium, San
Antonio, TX 82(1):S26 (#126), 2003.
25. Cristofanilli M, Krishnaumurthy S, Guerra L, Arun B, Walters R, Booser DJ, Green MC, Kau
S-W, Menander K, Van Wart HJ, Valero V, Hortobagyi, GN. Advexin (Ad5CMV-p53)
combined with Docetaxel (T) and Doxorubicin (D) as induction chemotherapy (IC): significant
efficacy of a novel gene-therapy approach for patients with locally advanced breast cancer
(LABC). 27th Annual San Antonio Breast Cancer Symposium 88(1):S61 (#1058), 2004.
26. Eralp Y, Smith TL, Kau SW, Valero V, Buzdar A, Hortobagyi GN, Arun B. Body mass index
(BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized
breast cancer aged 35 years or younger. Proc Am Soc Oncol 23:27 (#600), 2004.
27. Ozlem E, Frye D, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast
cancer patients with liver metastases only treated with chemotherapy. 29th ESMO Congress
15(3):iii46 (#175P), 2004.
28. Arun B, Lammey J, Broglio K, Valero V, Babiera G, Browne D, Hortobagyi GN, Sneige N.
Downregulation of Estrogen receptor expression with Celecoxib in breast tissue of women at
increased risk for developing breast cancer. 27th Annual San Antonio Breast Cancer
Symposium 88(1):S157 (#4026), 2004.
29. Cabioglu N, Yazici MS, Arun B, Smith TL, Hortobagyi GN, Price JE, Sahin A. Expression of
CCR4 predicts lymph node ;metastasis in early breast cancer. Proc Am Soc Oncol 23:837
(#9525), 2004.
30. Carlson RW, Schurman CM, Rivera E, Chung CT, Phan S-C, Dice EK, Arun B, Thomas E,
Valero V. Goserelin plus Anastrozole for the treatment of pre-menopausal women with
hormone receptor positive, recurrent/metastatic breast cancer. 27th Annual San Antonio
Breast Cancer Symposium 88(1):S237 (#6052), 2004.
31. Cabioglu N, Yazici MS, Arun B, Smith T, Hortobagyi GN, Price JE, Sahin AA. Novel
biomarkers predicting axillary lymph node metastasis in small size breast cancer. 27th
Annual San Antonio Breast Cancer Symposium 88(1):S69 (#3006), 2004.
32. Esteva FJ, Madden TL, Lammey J, Symmans WF, Booser DJ, Arun B, Rivera E, Brewster
AM, Valero V, Hortobagyi GN. Phase I and pharmacokinetic (PK) study of oblimersen, a
proapoptotic Bcl-2 targeting oligonucleotide, in a combination with Doxorubicin and Docetaxel
in metastatic and locally advanced breast cancer (BC). Proc Am Soc Oncol 23:224 (#3117),
2004.
Page 12 of 26
Banu Arun, MD
33. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung M-C, Kuerer HM. Significant differences in ductal fluid protein
expression in healthy women versus those with breast cancer identified by time-of-flight mass
spectrometry. 27th Annual San Antonio Breast Cancer Symposium 88(1):S189 (#5018),
2004.
34. Arun B, Dice K, Albarracin C, Rivera E, Walters R, Theriault R, Booser D, Bast R, Cristofanili
M, Sahin A, Smith TL, Hortobagyi GN. The combination of Letrozole and Imatinib Mesylate
for metastatic breast cancer. 27th Annual San Antonio Breast Cancer Symposium 88(1):S235
(#6046), 2004.
35. Gonzalez-Angulo AM, Broglio K, Kau S-W, Erlap Y, Erlichman J, Valero V, Booser D, Buzdar
AU, Hortobagyi GN, Arun B. Women Age 35 years or younger with primary breast
carcinoma: disease features at presentation. 29th ESMO Congress 15:iii58 (#220P), 2004.
36. Eder JP, Hidalgo M, Mendelson D, Ryan PD, Arun B, Lovalvo J, Eiseman I, Olson S,
Lenehan P. A phase I clinic and pharmacokinetic (PK) study of oral CI-1033 + Docetaxel
(DOC) in the treatment of patients with advanced solid tumors. JCO 23(16S):219s (#3111),
2005.
37. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V,
Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess K,
Zhang W, Hortobagyi GN, Pusztai L. A single gene biomarker identifies undifferentiated
breast cancers associated with short duration of breastfeeding. Breast Cancer Research and
Treatment 94:s248 (#6002), 2005.
38. Arun B, Mohsin A, Miller A, Isaacs C, Saxton K, Hilsenbeck S, Lamph W, Johnson K, Brown
P, Elledge R. Acquisition of breast tissue in a biomarker modulation study using bexarotene
in women at high risk of breast cancer. JCO 23(16S):106s (#1002), 2005.
39. Sneige N, Gong Y, Lammey J, Valero V, Babiera G, Kuerer H, Hortobagyi G, Arun B.
Baseline proliferation markers and cytophatholic finds in breast epithelium of women at
increased risk for breast cancer. JCO 23:884s (#9694), 2005.
40. Arun B, Valero V, Hornbeak J, Gong Y, Broglio K, Logan C, Browne D, Hortobagyi G, Sneige
N. Celecoxib downregulates estrogen receptor expression in breast tissue of women at
increased risk for developing breast cancer. Breast Cancer Research and Treatment 94:s169
(#4013), 2005.
41. Altundag K, Kim E, Broglio K, Buzdar AU, Hortobagyi GN, Arun B. Characterization of bone
mineral density (BMD) at the time of diagnosis in postmenopausal patients with operable
breast cancer; Association with clinical-pathological findings. JCO 23(16S):864s (#9611),
2005.
42. Garcia MKP, Arun B, Albarracin C, Sneige N. Estrogen receptor (ER) expression in breast
fine needle aspirates (FNA) of women at increased risk for breast carcinoma. Proc Amer
Assoc Cancer Res 46:2106, 2005.
43. Erlichman J, Valero V, Lu K, Rivera E, Strong L, Arun B:. Genetic testing for BRCA1 and
BRCA2 mutations in the Hispanic population. Breast Cancer Research and Treatment
94:s166 (#4004), 2005.
44. Symmans WF, Sotiriou C, Anderson SK, Hatzis C, Valero V, Booser DJ, Larsimont D,
Desmedt C, Gold DL, Sneige N, Cristofanilli M, Arun B, Gong Y, Ross JS, Hess K, Piccart
MJ, Harris AL, Hortobagyi GN, Pusztai L. Measurements of estrogen receptor and reporter
genes from microarrays determine receptor status and time to recurrence following adjuvant
tamoxifen therapy. Breast Cancer Research and Treatment 94:s32 (#308), 2005.
45. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P,
Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L.
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. PNAS
102:8315-8320, 2005.
46. Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H, Cohen
L. Randomized trial of yoga in women with breast cancer undergoing radiation treatment. The
2nd International Conference of the Society of Integrative Oncology, 2005.
47. Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H, Cohen
L. Randomized trial of yoga in women with breast cancer undergoing radiation treatment.
International Yoga Conference, Bangalore, India, 2005.
Page 13 of 26
Banu Arun, MD
48. Uyei A, Erlichman J, Lu K, Meric-Bernstam F, Strong L, Arun B. Risk reduction choices of
women with deleterious BRCA1 and BRCA2 mutations at a single institution. Breast Cancer
Research and Treatment 94:S25 (#110), 2005.
49. Deepali G, Sneige N, Katz R, Tarco E, Valero V, Babiera G, Green M, Hortobagyi GN, Arun
B. Telomere length assessment in fine needle aspiration specimens of breast in women at
high risk of breast cancer. Proc Amer Assoc Cancer Res 46:5727, 2005.
50. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Sneige N, Buchholz TA, Hunt KK,
Meric-Bernstam F, Arun B, Kuerer HM. The clinical impact of proliferative high-risk lesions
presenting concurrently with ductal carcinoma in situ (DCIS) in patients (pts) treated with
breast conserving therapy (BCT). JCO 23(16S):36s (#632), 2005.
51. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Vaero V, Theriault R, Booser
D, Buzdar AU, Hortobagyi GN, Arun B. Women age 35 or younger with Primary Breast
Carcinoma. Cancer, 2005.
52. Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H, Cohen
L. Randomized trial of yoga in women with breast cancer undergoing radiation treatment.
American Psychosomatic Society Conference, Denver, 3/2006.
53. Vogel k, Atchley D, Erlichman J, Broglio K, Ready K, Amos C, Lu K, Valero V, Strong L,
Hortobagyi G, Arun B. Evaluation of the BRCAPRO model in a cohort of Hispanic families.
American Association for Cancer Research International Conference on Frontiers in Cancer
Prevention Research; (#A32), 11/2006.
54. Mazouni C, Hall A, Anderson K, Peintinger F, Fritsche H, Andre F, Yekell S, Arun B, Buzdar
AU, Esteva F, Pusztai L, Cristofanilli M. An early decrease in serum HER-2/neu levels after
initiation of primary chemotherapy for HER-2 positive breast cancer indicates response to
treatment. SABCS (#1039), 2006.
55. Uyei A, Broglio K, Solomon T, Vogel K, Amos C, Lu K, Meric-Bernstam F, Strong L, Arun B.
Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for
the BRCA 1/2 genetic mutation. J Clin Oncol 24:18s (#1013), 2006.
56. Huflejt M, Vuskovic M, Mazouni C, Vasiliu D, Xu H, Chambers J, Buzdar A, Arun B, Bovin N,
Cristofanilli M, Pusztai L. Detection of anti-glycan autoantibodies with printed glycan arrays in
primary breast cancer: diagnostic and predictive antibody signatures. SABCS (#3150), 2006.
57. Solomon TL, Vogel KJ, Atchley DP, Amos C, Valero V, Meric F, Hortobagyi G, Arun B. Highrisk precursor lesions observed in breast cancer patients who are positive for BRCA1 or
BRCA2 mutations. SABCS (#5114), 2006.
58. Yang WT, Dryden M, Broglio K, Meric-Bernstam F, Valero V, Arun B. Mammographic and
sonographic features of breast cancer in young women at high genetic risk. SABCS (#4037),
2006.
59. Arun B, Valero V, Yin G, Babiera G, Murray J, Browne D, Gong Y, Cook E, Hortobagyi G,
Sneige N. Phase II breast cancer chemoprevention study with celecoxib in women at
increased risk for breast cancer. J Clin Oncol 24:18s (#1010), 2006.
60. Rivera E, Meija J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Esteva F,
Hortobagyi G, Valero V. Phase II study of docetaxel weekly (DW) versus every 3 weeks (D)
in patients with metastatic breast cancer: Final results. J Clin Oncol 24:18s (#574), 2006.
61. Arun B, Valero V, Logan C, Rivera E, Brewster A, Green M, Buzdar A, Browne D, Hortobagyi
GN, Sneige N. Random periareolar fine needle aspiration compared to ductal lavage for
tissue acquisition in short-term breast cancer chemoprevention studies. SABCS (#1048),
2006.
62. Cohen L, Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra
H. Randomized trail of yoga in women with breast cancer undergoing radiation treatment. J
Clin Oncol 24:469s (#8505), 2006.
63. Ready K, Voguel K, Atchley D, Amos C, Solomon K, Lu K, Arun B. BRCA mutations among
women with bilateral breast cancer: mutation carrier rate and sensitivity of the BRCAPRO
model based on age at first diagnosis. SABCS, 2007.
64. Arun B, Vuskovic M, Vasiliu D, Xu HY, Atchley D, Chambers J, Bovin N, Sneige N,
Hortobagyi GN, Hufleit M. Immunomodulatory effects of celecoxib in patients at increased
risk for breast cancer. SABCS (#4041), 2007.
Page 14 of 26
Banu Arun, MD
65. Sun CC, Westin SN, Lu KH, Schmeler KM, White KG, Daniels MS, Arun B, Peterson SK,
Bodurka DC. Impact of BRCA 1/2 testing: Body image, sexual functioning, and quality of life
(QOL). ASCO (#1525), 2007.
66. Yang WT, Dryden M, Broglio K, Dawood S, Valero V, Hortobagyi G, Atchley D, Arun B.
Mammographic features of Triple-negative versus HER2+ AND ER+ breast cancers. SABCS
(#1025), 2007.
67. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, White KG, Daniels MS, Arun B,
Peterson SK, Bodurka DC. Management strategies for women at high risk for breast and
ovarian cancer: Are women satisfied? ASCO (#1524), 2007.
68. Arun B, Logan C, Yin G, Yun G, Hortobagyi G, Browne, G, Sneige, N. Phase II prevention
trial of celecoxib in women at increased risk for breast cancer. ASCO (#1501), 2007.
69. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam F, Lu K,
Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA variants of
uncertain significance. JCO 26(15s):750s (#22021), 5/2008.
70. Yang W, Sahin A, Wong H, Tsimelzon A, Hess K, Karadag N, Cairo M, Meric F, Arun B,
Chang J. Molecular portraits of mammorgraphic breast density in normal breast tissue. JCO
26(15s):767s (#22227), 5/2008.
71. Cohen L, Chandwani K, Perkins G, Thornton B, Arun B, Raghuram N, Nagendra H.
Randomized trail of yoga in women with breast cancer undergoing radiation treatment: Longterm effects. JCO 26(15s):536s (#9639), 5/2008.
72. Arun B, Atchley D, Litton J, Pusztai L, Valero V, Hortobagyi G, Albarracin C. Response to
neoadjuvant chemotherapy in BRCA1 and BRCA2 related breast cancers. JCO 26(15s):35s
(#618), 5/2008.
73. Ready K, Arun B, Litton J, Uyei A, Schmeler K, Lu K, Sun C, Peterson S. Communication of
BRCA1 and BRCA2 genetics test results to primary care physicians. In Press.
74. Akar U, Ozpolat B, Mehta K, Lopez-Berenstein G, Hortobagyi G, Arun B. Targeting P70S6K
prevented lung metastasis in a breast cancer xenograft model. American Association for
Cancer Research. Submitted.
Book Chapters
1. Arun B, Philips M. Breast Cancer in Adolescents and Young Adults. In: AYA Monograph,
2000.
2. Arun B, Kessler CM. Clinical Manifestations and Therapy of the Hemophilias. In: Hemostasis
and Thrombosis: Basic Principles and Clinical Practice, 4th, 815-824, 2001.
3. Arun B, Hortobagyi GN. Chimioterapia Adjuvant| Õi Hormonoterapia Cancerului Mamar
Primar. Chapter 17. In: Tratamentul Conservator al Cancerului Mamar Incipient. Editura
Universitar| Carol Davila, 275-295, 2003.
4. Arun B, Strong L. Breast Cancer Genetic Syndromes. In: Advanced Therapy of Breast
Disease, 2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 75-83, 2004.
5. Arun B. Ductal Lavage in Risk Reduction. In: Advanced Therapy of Breast Disease, 2nd.
B.C. Decker Inc. Publishers: Ontario, Canada, 113-119, 2004.
6. Arun B, Kuerer H. Breast Cancer Risk Assessment and Management. In: Breast Cancer,
2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 2005.
7. Arun B. Breast Cancer Risk Assessment and Management. In: Breast Cancer, 2nd. Ed(s)
Winchester and Winchester,. B.C. Decker Inc, 2005.
8. Bottom K, O'Leary M, Sheaffer J, Phillips M, Shu X-O, Arun B. Cancer Epidemiology in Older
Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and
Survival. In: Breast Cancer. Ed(s) Bleyer A, O’Leary M, Barr R, Lag R. National Cancer
Institute, NIH Pub No. 06-5767.: Bethesda, MD, 111-121, 2006.
9. Arun B, Ready K. Genetic Predisposition to Breast Cancer and Genetic Counseling and
Testing. In: Springer, 2nd. Ed(s) Hunt KK, Robb GL, Strom EA, Ueno NT, Robb G, 57-82,
2007.
10. Arun B, Ready K. Hereditary breast cancer genetic predisposition to breast cancer [and
genetic counseling and testing]. In: Hunt KK, Robb GL, Strom EA, Ueno NT, eds. Breast
Cancer. New York: Springer Science+Business Media, 2007.
Page 15 of 26
Banu Arun, MD
Manuals, Teaching Aids, Other Teaching Publications
1. Arun B. Possible link discovered in Hispanic Women and Breast Cancer.
http://www.khou.com/topstories/stories/khou070430_ac_hispanicbreastcancer.23331c62.html
. CBS - KHOU TV: Houston, Texas,
http://www.khou.com/topstories/stories/khou070430_ac_hispanicbreastcancer.23331c62.html
, 4/2007.
2. Arun B,. The Role BRCA mutations play in breast cancer risk. circulation: 553,023,
September/October 2007. Golf for Women magazine article, 2007.
EDITORIAL AND REVIEW ACTIVITIES
Editor/Service on Editorial Board(s)
Editorial Board Member, Turkish Journal of Cancer, 2003−present
Member of Editorial Review Board
N/A
Journal Reviewer
Reviewer, Biomarkers & Prevention, present
Reviewer, Breast Cancer Research and Treatment, present
Reviewer, Cancer Epidemiology, present
Reviewer, Clinical Applied Hemostasis and Thrombosis, present
Reviewer, Clinical Cancer Research, present
Reviewer, Journal of Molecular Carcinogenesis, present
Reviewer, Journal of the National Cancer Institute, present
Reviewer, The Oncologist, present
Other Editorial and Review Activities
Peer Reviewer, American Society of Clinical Oncology Cancer Prevention Curriculum Book,
present
TEACHING
Teaching Within Current Institution - The University of Texas M. D. Anderson Cancer Center
Formal Teaching
Courses Taught
Instructor, Management for High Risk Breast Cancers, Breast-Gyn Day,
The University of Texas M. D. Anderson Cancer Center and The University of Texas
Health Science Center, Houston, TX
Fall, 10/2002
Instructor, Management for High Risk Breast Cancers, The University of Texas
M. D. Anderson Cancer Center and The University of Texas Health Science Center,
Houston, TX
3/2004
Instructor, Graduate School of Biomedical Sciences Cancer Genetic Counseling Course,
The University of Texas M. D. Anderson Cancer Center, Houston, TX, Course Number:
GS110012
1/2006
Instructor, Graduate School of Biomedical Sciences Translational Research Course,
Course Number: GS210232
1/2006
Page 16 of 26
Banu Arun, MD
Instructor, Graduate School of Biomedical Sciences Translational Research Course,
The University of Texas M. D. Anderson Cancer Center, Houston, TX, Course Number:
GS21 0232
1/2007
Training Programs
Breast Cancer Chemoprevention, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
12/2000
Preceptorship Clinical Exchange Program Educational Review Course: Update on
Hormonal Management for Metastic Breast Cancer, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
11/2001
Preceptorship Clinical Exchange Program Review Course: New Chemotherapeutic
Treatment Options for Metastatic Breast Cancer, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
11/2001
Chemoprevention Advances in the Treatment of Metastatic Breast Cancer,
The University of Texas M. D. Anderson Cancer Center, Houston, TX
4/2002
Preceptorship Current Management of Breast Cancer with Chemotherapy and Hormonal
Therapy- Adjuvant, The University of Texas M. D. Anderson Cancer Center, Houston, TX
8/2002
Preceptorship Current Management of Breast Cancer with Chemotherapy and Hormonal
Therapy- Metastatic, The University of Texas M. D. Anderson Cancer Center, Houston,
TX
8/2002
Preceptorship Management of Breast Cancer Preceptorship Program for Spanish
Oncologist, The University of Texas M. D. Anderson Cancer Center, Houston, TX
3/2003
Prevention of Breast Cancer, The University of Texas M. D. Anderson Cancer Center,
Surgery Fellows, Houston, TX
4/2003
Multitargeted Therapy: Combination with Endocrine Treatment, Breast Cancer Research
Group Spring Retreat, The University of Texas M. D. Anderson Cancer Center, Houston,
TX
5/2003
Breast Cancer Risk Assessment and Prevention-Beyond Tamoxifen,
The University of Texas M. D. Anderson Cancer Center, Gynecology Oncology Grand
Rounds, Houston, TX
7/2003
Breast Cancer Risk Assessment and Prevention-Beyond Tamoxifen,
The University of Texas M. D. Anderson Cancer Center, Division of Pathology and
Laboratory Medicine Grand Rounds, Houston, TX
2/2004
Breast cancer prevention, The University of Texas M. D. Anderson Cancer Center
Surgical Oncology Grand Rounds Conference, Houston, TX
12/2004
Page 17 of 26
Banu Arun, MD
Types of treatment for breast cancer, The University of Texas
M. D. Anderson Cancer Center- Information Line, Houston, TX
1/2005
Management for High Risk Breast Cancers: Screening, chemoprevention, prophylactic
surgeries, The University of Texas M. D. Anderson Cancer Center, Clinical Cancer
Genetics, Houston, TX
3/2005
Current Status of Chemoprevention, The University of Texas
M. D. Anderson Cancer Center Symposium - First Annual Breast and Prostrate Cancer
Update in Kauai, HI
6/2005
Use of Adjuvant Hormonal Therapy in the Treatment of Breast Cancer,
The University of Texas M. D. Anderson Cancer Center Symposium - First Annual Breast
and Prostrate Cancer Update in Kauai, HI
6/2005
Translational Studies in Cancer Disposition Syndromes, Graduate School of Biomedical
Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX
4/2006
Instructor, Hereditary Breast Cancer Screening and Counseling, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
10/2006
Lecturer, Breast Cancer Genetic Risk Assessment and Management Options,
The University of Texas M. D. Anderson Cancer Center, Houston, TX
4/2007
Direct Supervision
Graduate Students
Thesis Mentor, Graduate School of Biomedical Sciences, Stacey Miller,
1/2006−8/2006
Thesis Mentor, Graduate School of Biomedical Sciences, Laura Amendola,
1/2008−present
Postdoctoral Research Fellows
N/A
Clinical Residents and Fellows
Anne Uyei, 2004−2005
Jenniffer Litton, 2006−2007
Other Supervisory Teaching
Member, Thesis, Graduate School of Biomedical Sciences, Matthew L. Tschirgi, Thesis,
2008
Mentor, 2009 ASCO IDEA Program, 2009 IDEA Mentor, Raafat Abdel
Teaching Outside of Current Institution
Formal Teaching
Training Programs
Breast Cancer Chemoprevention and Evaluation of High Risk Patients, UT M.D.
Anderson Cancer Center P, Schering-Plough Pharmaceuticals, Houston, TX
3/2003
Page 18 of 26
Banu Arun, MD
Prevention and Early Detection of Breast Cancer, JoAnn Rosenberg Fund's Free
Education Program About Breast and Ovarian Cancer, Houston, TX
3/2004
Instructor: Risk assessment of hereditary breast cancer, Gynecology Oncology Fellows
Lecture
10/2004
Track Leader, Cancer Prevention/Epidemiology, American Society of Clinical Oncology
9/2007−8/2008
Other Formal Teaching
Instructor, The Evaluation and Management of Familial and Genetic Risk in Individuals at
High Risk for Breast Cancer, Medscape-http://www.medscape.com/viewprogram/14812,
Course Number: 6FDKKC-PRV-05, Course Hours: 1.0
2008−present
CONFERENCES AND SYMPOSIA
Organization of Conferences/Symposia (Include chairing session)
1st Congress of the World Society for Breast Health, Instanbul, Turkey, Chair, 9/2001
American Association of Cancer Research, Denver, CO, Chair, 4/2009
Presentations at National or International Conferences
Invited
Clinical aspects of BRCA 1 and BRCA 2 mutations in Breast Cancer, 1st Congress of the
World Society for Breast Health, Istanbul, Turkey, 9/2001
Ductal lavage in the management of high-risk women, 3rd Annual Lynn Sage Breast Cancer
Symposium, Chicago, IL, 10/2001
Growth Inhibition of Breast Cancer Cells by Celecoxib poster presentation, 24th Annual San
Antonio Breast Cancer Symposium, San Antonio, TX, 12/2001
A Phase I Study of Gemcitabine and Vinorelbine in Metastatic Breast Cancer who are Heavily
Pretreated with Chemotherapy, 12th International Congress on Anti-Cancer Treatment, Paris,
France, 2/2002
Management of Women at High Risk for Breast Cancer, 7th Annual National Comprehensive
Cancer Network Conference: Practice Guidelines and Outcomes Data in Oncology, Tampa,
FL, 3/2002
Management of Women at High Risk for Breast Cancer, Joint Conference
The University of Texas M. D. Anderson Cancer Center: Recent Advances in the
Management of Breast Cancer, Kuwait Cancer Control Center, Kuwait City, Kuwait, 4/2002
Management of Women at Increased Risk for Breast Cancer, Summer Seminar for Breast
Cancer Diagnosis & Treatment, Summer Seminar for Breast Cancer Diagnosis & Treatment.
St. Luke's Medical Hospital, Tokyo, Japan, 7/2002
COX-2: A rationale target for the prevention and treatment of cancer., Oncology Consultants
Meeting. Chaired session: Role of COX-2 inhibition in Breast Cancer Treatment and
Prevention, Palm Beach, FL, 10/2002
Panel Discussion on Current and Future Use of Ductal Lavage, 25th Annual San Antonio
Breast Cancer Conference, San Antonio, TX, 12/2002
Bcl-Expression Predicts Regional Lymph Node Metastasis in Early Breast Cancer, 2003
Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 6/2003
Beyond mammograms-new methods for early detection of breast cancer, Early Detection of
Women's Cancers Learning Through Case Presentations, Houston, TX, 6/2003
Page 19 of 26
Banu Arun, MD
Future novel approaches for the treatment of breast cancer, 2003 Breast Cancer Symposium,
Paradigms of Breast Cancer in New Millennium, Mexico City, 6/2003
Risk assessment and prevention of breast cancer, 2003 Breast Cancer Symposium,
Paradigms of Breast Cancer in New Millennium, Mexico City, 6/2003
Management of Women at Increased Risk for Breast Cancer, Summer Seminar for Breast
Cancer Diagnosis & Treatment, University Hospital, Augusta, GA, 10/2003
Adjuvant chemotherapy in breast cancer, Grand Rapids Clinical Oncology Program
Distinguished Lecture Series 2003, Grand Rapids, MI, 11/2003
Pilot Study of Biomarker Modulation with Celecoxib Using Ductal Lavage, NIH COX-2
Inhibitors for Breast Cancer Prevention Studies, Biomarker Development Meeting, Orlando,
FL, 3/2004
Current hormonal treatments for adjuvant breast cancer, University of North Texas Health
Science Center at Fort Worth, Oak Brook, IL, 5/2004
Breast cancer update, University of California at Irvine Department of Oncology Grand
Rounds, Orange, CA, 10/2004
Clinical course of breast cancer patients with liver metastases only treated with
chemotherapy, 29th ESMO Congress, Vienna, Austria, 10/2004
Women age 35 years or younger with primary breast carcinoma: disease features at
presentation, 29th ESMO Congress, Vienna, Austria, 10/2004
Risk Assessment and Prevention of Breast Cancer and Role of Ductal Lavage in Risk
Assessment and Prevention of Breast Cancer, Caring for Women with High Risk Breast
Lesions, Belgian Society of Senology, Brussels, Belgium, 2/2005
COX-2 inhibitors for the prevention of breast cancer, 4th International Symposium on the
Intraductal Approach to Breast Cancer, Santa Barbara, CA, 3/2005
Managing breast cancer risk: enhanced surveillance (MRI, US) and chemoprevention,
American Society of Breast Surgeons Sixth Annual Meeting, Los Angeles, CA, 3/2005
Hormonal management of breast cancer, Middle East Oncology Symposia on Recent
Advances in Breast Cancer and Colorectal Cancer Management, Dubai, United Arab
Emirates, 4/2005
Telomere length assessment in fine needle aspiration specimens of breast in women at high
risk of breast cancer, American Association for Cancer Research, Anaheim, CA, 4/2005
Acquisition of Breast Tissue in a Biomarker using Bexarotene in Women at High Risk of
Breast Cancer, American Society of Clinical Oncology, Orlando, FL, 5/2005
Characterizations of bone mineral density at the time of diagnosis in post menopausal
patients with operable breast cancer., American Society of Clinical Oncology, Orlando, FL,
5/2005
The clinical impact of proliferative high-risk lesions presenting concurrently with ductal
carcinoma in situ (DCIS) in patients (pts) treated with breast conserving therapy (BCT), 2005
Annual American Society of Clinical Oncology, Orlando, FL, 5/2005
Chemoprevention Agents, 8th Annual Targeted Therapies for the Treatment of Breast
Cancer, Dana Point, CA, 7/2005
Breast Cancer Risk Assessment and Prevention, 8th National Breast Cancer Congress,
Istanbul, Turkey, 9/2005
A single gene biomarker identifies undifferentiated breast cancers associated with short
duration of breastfeeding, (abst 6002), 28th Annual San Antonio Breast Cancer Symposium,
San Antonio, TX, 12/2005
Page 20 of 26
Banu Arun, MD
Celecoxib downregulates estrogen receptor expression in breast tissue of women at
increased risk for developing breast cancer, (Poster, abst 4013), 28th Annual San Antonio
Breast Cancer Symposium, San Antonio, TX, 12/2005
Genetic testing for BRCA1 and BRCA2 mutations in the Hispanic population, (Poster, abst
4004), 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2005
Measurements of estrogen receptor and reporter genes from microarrays determine receptor
status and time to recurrent following adjuvant tamoxifen therapy, (abst 308), 28th Annual
San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2005
Risk reduction choices of women with deleterious BRCA1 and BRCA2 mutations at a single
institution (Poster Discussion, abst 110), 28th Annual San Antonio Breast Cancer
Symposium, San Antonio, TX, 12/2005
Genetic Risk Assessment and Prevention of Breast Cancer, 11th Annual Multidisciplinary
Oncology Meeting, Lisbon, Portugal, 1/2006
Role of Breast Health Management and Breast Cancer Prevention Breast Cancer Risk
Assessment and Chemoprevention, Society of Gynecologic Oncology, Palm Springs, CA,
3/2006
High Risk Patients: Can We Really Prevent Breast Cance, The University of Texas
M. D. Anderson Cancer Center Symposium - Second Annual Symposium, Kauai, HI, 6/2006
Interventional Breast Cancer Prevention, Oral Presentation, American Society of Clinical
Oncology, Atlanta, GA, 6/2006
Use of Adjuvant Hormonal Therapy in the Treatment of Breast Cancer,
The University of Texas M. D. Anderson Cancer Center Symposium - Second Annual
Symposium, Kauai, HI, 6/2006
Controversies in Breast Cancer (Oral Presentation), Adjuvant and Neoadjuvant Therapy
Conference, New York, NY, 9/2006
Extending the span of patient care in breast cancer: Adjuvant risk reduction, 31st European
Society for Medical Oncology Congress, Istanbul, Turkey, 9/2006
Management of Genetic risk and preneoplastic lesions: Ongoing protocols at
The University of Texas M. D. Anderson Cancer Center, International Gustave RoussyThe University of Texas M. D. Anderson Cancer Center Scientific Symposium, Paris, France,
9/2006
Breast cancer risk reduction and chemoprevention strategies in high-risk women, North
American Menopause Society, Nashville, TN, 10/2006
Evaluation of the BRCAPRO model in a cohort of Hispanic families. Poster, American
Association for Cancer Research International Conference on Frontiers in Cancer Prevention
Research, Boston, MA, 11/2006
An early decrease in serum HER-2/neu levels after initiation of primary chemotherapy for
HER-2 positive breast cancer indicates response to treatment., 29th San Antonio Breast
Cancer Symposium, San Antonio, TX, 12/2006
Detection of anti-glycan autoantibodies with printed glycan arrays in primary breast cancer:
diagnostic and predictive antibody signatures., 29th San Antonio Breast Cancer Symposium,
San Antonio, TX, 12/2006
High-risk precursor lesions observed in breast cancer patients who are positive for BRCA1or
BRCA2 mutations., 29th San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2006
Mammographic and sonographic features of breast cancer in young women at high genetic
risk., 29th San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2006
Page 21 of 26
Banu Arun, MD
Random periareolar fine needle aspiration compared to ductal lavage for tissue acquisition in
short-term breast cancer chemoprevention studies., 29th San Antonio Breast Cancer
Symposium, San Antonio, TX, 12/2006
Distant disease free survival a primary suitable endpoint for new clinical trails, Oral
Presentation, Breast Cancer Opinion Leader Summit, Montreux, Switzerland, 2/2007
Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for
the BRCA1/2 genetic mutation., American Society of Clinical Oncology Conference, Chicago,
IL, 6/2007
Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for
breast cancer., American Society of Clinical Oncology Conference, Chicago, IL, 6/2007
Phase II prevention trial of celecoxib in women at increased risk for breast cancer. Oral
Presentation, American Society of Clinical Oncology Conference, Chicago, IL, 6/2007
Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with
metastatic breast cancer: Final results., American Society of Clinical Oncology Conference,
Chicago, IL, 6/2007
Randomized trial of yoga in women with breast cancer undergoing radiation treatment.,
American Society of Clinical Oncology Conference, Chicago, IL, 6/2007
Changing the face of endocrine therapy for breast cancer., 9th National Breast Diseases
Congress Conference, Ankara, Turkey, 9/2007
Neoadjuvant chemotherapy in the treatment of breast cancer; the role of Herceptin., 9th
National Breast Diseases Congress Conference, Ankara, Turkey, 9/2007
Building a Predictive Breast Cancer Risk Model, American Medical Informatics Association
Annual Symposium, Chicago, IL, 11/2007
Association of body mass index and breast cancer in hereditary breast cancer cases: A pilot
Study, American Association for Cancer Research Prevention Meeting, Philadelphia, PA,
12/2007
BRCA mutations among women with bilateral breast cancer: mutation carrier rate and
sensitivity of the BRCAPRO model based on age at first diagnosis, 30th Annual San Antonio
Breast Cancer Symposium, San Antonio, TX, 12/2007
Immunomodulatory effects of celecoxib in patients at increased risk for breast cancer, 30th
Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2007
Mammographic features of triple-negative versus HER2+ and ER+ breast cancers, 30th
Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2007
Response to neoadjuvant chemotherapy in BRCA1 and BRCA2 related breast cancers,
American Society of Clinical Oncology Annual Meeting, Chicago, IL, 6/2008
Targeting P70S6K prevented lung metastasis in a breast cancer xenograft model, American
Association for Cancer Research, Denver, CO, 4/19/2009
Arun B, Valero V, Brewster A, Gutierrez A, Green M, Esteva F, Buzdar A, Hortobagyi GN,
Sneige N. A short-term biomarker modulation prevention study of anastrazole in women at
increased risk for breast cancer, American Society of Clinical Oncology Conference, Orlando,
FL, 5/2009
A short-term biomarker modulation prevention study of anastrazole in women at increased
risk for breast cancer, American Society of Clinical Oncology, Denver, CO, 5/2009
Factors leading to the decision for contralateral prophylactic mastectomy in patients with
breast cancer, American Society of Clinical Oncology, Denver, CO, 5/2009
Page 22 of 26
Banu Arun, MD
Yi m, Hunt KK, Arun B, Bedrosian I, Gutierrez-Barrera AM, Kuerer HM, Babiera G, Mittendorf
EA, Meric-Bernstam F. Factors leading to the decision for contralateral prophylactic
mastectomy in patients with breast cancer, American Society of Clinical Oncology
Conference, Orlando, FL, 5/2009
Racial differences in the use of contralateral prophylactic mastectomy among women
undergoing BRCA1/BRCA2 genetic testing, American Society of Clinical Oncology, Denver,
CO, 5/2009
Other, Including Scientific Exhibitions
Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Meric-Bernstam F, Lu KH, GonzalezAngulo AM, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers
in subsequent generations, 2009 Breast Cancer Symposium, San Francisco, CA, 10/2009
Arun B, Murray JL, Walters R, Brewster A, Rivera E, Valero V, Bast R, Theriault RL, Green
M, Hortobagyi GN. The combination of letrozole and imatinib mesylate for metastatic breast
cancer, 2009 Breast Cancer Symposium, San Francisco, CA, 10/2009
Seminar Invitations from Other Institutions
Reducing the incidence of breast cancer in women with high risk, Tumor Grand Rounds, United
Regional Health Care System, 10/1999
Update on chemotherapeutic options for metastatic breast cancer, Oncology Grand Rounds,
University of Oklahoma, OK, 3/2001
Hormonal treatment options for metastatic breast cancer, Tumor Grand Rounds, Integris Health
System Hospital, OK, 4/2001
Management of Breast Cancer, Combined Oncology Modality Conference Series, University of
Texas Houston Medical School, Houston, TX, 5/2001
Update on the Chemotherapeutic Management of Breast Cancer, Breast Cancer 2001Symposium, The Don and Sybil Harrington Cancer Center, Texas Tech University Health Science
Center, Amarillo, TX, 10/2001
Screening and Prevention of Breast Cancer, Regional Medical Center, Tampa, FL, 11/2001
Genetic Counseling for Breast Cancer, University of Basel Oncology Grand Rounds, Basel,
Switzerland, 2/2002
Breast Cancer, Grand Rounds, Mount Sinai Hospital, Department of Obstetrics and, Chicago, IL,
5/2002
Pilot Study with a COX-2 Inhibitor, Ductal Lavage, A Workshop for Program Development (NCI),
Bethesda, MD, 9/2003
Advances and Controversies in High Risk Breast Cancer, 2005 Louisville Breast Cancer Update,
University of Louisville Health Sciences Center, Louisville, KY, 9/2005
Current Application of the New Diagnostics, The Emerging Role of Screening & Prevention in
Women's Cancers Symposium, New York University Post-Graduate Medical School, New York,
NY, 5/2006
The Emerging Role of Screening & Prevention in Women's Cancers. Poster Discussion
Moderator, The Emerging Role of Screening & Prevention in Women's Cancers Symposium, New
York University Post-Graduate Medical School, New York, NY, 5/2006
Optimizing Adjuvant Hormonal Therapy for Post menopausal Women With Breast Cancer, Grand
Round, Community Memorial Hospital, Ventura, CA, 11/2006
Optimizing Adjuvant Hormonal Therapy for Post menopausal Women With Breast Cancer, Grand
Round, Harbor Hospital, Baltimore, MD, 2/2007
Page 23 of 26
Banu Arun, MD
Breast Cancer Prevention-Beyond Tamoxifen, Winship Cancer Institute, Emory University,
Atlanta, GA, 3/2007
Optimizing Adjuvant Hormonal Therapy for Post menopausal Women With Breast Cancer, Grand
Round, University of Maryland School of Medicine, Baltimore, MD, 3/2007
Breast Cancer Prevention: Beyond Tamoxifen, Oncology Grand Rounds, Winship Cancer
Institute Emory University, Atlanta, GA, 1/2008
Breast Cancer Risk Assessment and Prevention Studies at UT M.D. Anderson Cancer Center,
Grand Rounds, Women's College Research Institute, Toronto, Toronto, Canada, 1/2008
Breast Cancer Prevention, Kansas Masonic Cancer Research Institute Round Table Seminar,
University of Kansas Medical Center, Orlando, FL, 3/2008
Cancer Genetics, Risk Assessment and Prevention, Grand Rounds, The University of M. D.
Anderson Cancer Center, Fellowship Program, Orlando, FL, 4/2008
Breast Cancer Prevention: Beyond SERM's, Grand Rounds, Columbia University Medical Center,
Divisions of Hematology and Medical Oncology, New York, NY, 5/2008
Breast Cancer Risk Assessment & Prevention: The Role of Genetic Testing, 30th Annual Internal
Medicine Conference: Back to the Patient, The Orlando Regional Healthcare, Orlando, FL,
7/2008
Risk Reduction in Clinical Practice, Breast Cancer Current Controversies And New Horizons,
Harvard University, Women's Cancers Program Dana Farber Cancer Institute, Boston, MA,
7/2008
Lectureships and Visiting Professorships
Update on the Chemotherapeutic Management of Breast Cancer, Judith Pachtman Memorial
Lecture, Desert Samaritan, Mesa, AZ, 10/2001
Hereditary Breast Cancer: Risk Assessment and Management, Surgical Oncology Grand
Rounds, M.D. Anderson Cancer Center, Department of Surgical Oncology, Houston, TX,
2/5/2009
Other Presentations at State and Local Conferences
Non Hodgkin Lymphomas, Postgraduate Education Seminar, UT Southwestern Medical Center,
Dallas, TX, 9/1997
Chairman: Prognostic markers in breast cancer and chemoprevention, Spring Retreat,
The University of Texas M. D. Anderson Cancer Center, Breast Cancer Research Group,
Houston, TX, 3/2001
Breast Cancer Screening and Prevention, Outreach Program, Houston Junior League
Conference, Houston, TX, 9/2002
Breast Cancer Prevention, Outreach Program, Vinson and Elkins Law Firm, Houston, TX,
10/2002
Breast Cancer Prevention and Early Detection, Outreach Program, Marathon Oil Corporation,
Houston, TX, 10/2002
Breast Cancer Treatment Landscape and Patient Quality of Life Issues, Y-ME, Houston, TX,
11/2002
Breast Cancer Awareness and Developments in Breast Cancer Research, Komen Houston
Affiliate, Houston, TX, 1/2003
Adjuvant Therapy in Breast Cancer and The Role of the Primary Care Physician in the Treatment
of Breast Cancer, Coastal Bend Health Education Center's 10th Annual, Corpus Christi, TX,
4/2003
Page 24 of 26
Banu Arun, MD
Breast Cancer: Making the Most of What We Know, Healthy Woman's Symposium and
Luncheon, Houston, TX, 4/2003
Prevention of Breast Cancer, The University of Texas M. D. Anderson Cancer Center Surgery
Fellows, Houston, TX, 4/2003
Multitargeted Therapy: Combination with Endocrine Treatment, Spring Retreat, Breast Cancer
Research Group, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 5/2003
Panel Discussant, Breast Diseases Symposium, El Paso Cancer Treatment Center, El Paso, TX,
5/2003
The Role of Ductal Lavage in the Risk Assessment of Breast Cancer, Breast Diseases
Symposium, El Paso Cancer Treatment Center, El Paso, TX, 5/2003
Implementing Risk Assessment: Changing The Breast Cancer Risk Paradigm, Houston
Gynecological & Obstetrical Society, Houston, TX, 9/2003
Risk Assessment and The Prevention of Breast Cancer, Living Fully with Cancer Patient
Conference, Houston, TX, 9/2003
Breast Cancer Treatment Landscape and The Importance of Clinical Trials, Y-ME Town Hall
Meeting, Houston, TX, 11/2003
Breast Cancer Screening, Prevention and Detection, The Texas A&M Health Science Center,
McAllen, TX, 4/2004
Update on Hormonal Therapy in Adjuvant Breast Cancer, University of North Texas Health
Science Center, Houston, TX, 6/2004
Genetic Counseling and Breast Cancer, The University of Texas Medical Branch, Galveston, TX,
8/2004
Breast Cancer Panel Discussant, Young Survivors Coalition, Houston, TX, 10/2004
Breast Cancer Prevention, Sister's Network, Inc 7th Annual National African, Houston, TX,
4/2005
New Advances in the Treatment of Metastatic Breast Cancer, Brook Army Medical Center
Oncology Grand Rounds, San Antonio, TX, 4/2005
Hormonal Management of Early Breast Cancer, Texas A&M, Corpus Christi, TX, 6/2005
Translational Studies in Cancer Predisposition Syndromes, Graduate School of Biomedical
Sciences, Houston, TX, 4/2006
Clinical Approach to BRCA-1 Positive Patients., Fall Retreat, Breast Cancer Research Program,
The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2006
Breast Cancer Research Consortium Annual Meeting, Breast Cancer Research Consortium,
Dallas, TX, 2/2007
Ask the Expert Session, University Cancer Foundation Board of Visitors Annual Meeting,
The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2007
Breast Malignancies, Global Academic Programs Conference, The University of Texas
M. D. Anderson Cancer Center, The University of Texas M. D. Anderson Cancer Center,
Houston, TX, 6/2008
PROFESSIONAL MEMBERSHIPS/ACTIVITIES
Professional Society Activities, with Offices Held
National and International
American Society of Breast Disease
Member, 2001−2004
Page 25 of 26
Banu Arun, MD
American Society of Clinical Oncology
Member, 2001−2004
American Association for Cancer Research
Member, 2002−2004
International Society for Cancer Risk Assessment and Management
Founding Member, 2003−present
American Association for Cancer Research: Prevention Task Force
Member, 2005−present
American Society of Clinical Oncology, Cancer Prevention/Epidemiology Track
Member, 2005−present
National Comprehensive Cancer Network (NCCN) Breast Cancer Risk Reduction Panel
Member, 2005−present
American Society of Clinical Oncology, Cancer Education Track, Scientific Committee
Track Leader, 2007−present
American Society of Clinical Oncology Breast Symposium Program Committee
Member, 2009−2012
Page 26 of 26